Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Other financing activities (2016 - 2025)

Historic Other financing activities for Fortress Biotech (FBIO) over the last 12 years, with Q3 2025 value amounting to -$2000.0.

  • Fortress Biotech's Other financing activities changed N/A to -$2000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7000.0, marking a year-over-year change of. This contributed to the annual value of -$1000.0 for FY2024, which is N/A changed from last year.
  • Fortress Biotech's Other financing activities amounted to -$2000.0 in Q3 2025.
  • In the past 5 years, Fortress Biotech's Other financing activities registered a high of $275000.0 during Q4 2021, and its lowest value of -$6000.0 during Q3 2022.
  • Over the past 4 years, Fortress Biotech's median Other financing activities value was -$1000.0 (recorded in 2021), while the average stood at $34000.0.
  • Within the past 5 years, the most significant YoY rise in Fortress Biotech's Other financing activities was 25000.0% (2022), while the steepest drop was 50000.0% (2022).
  • Over the past 4 years, Fortress Biotech's Other financing activities (Quarter) stood at $275000.0 in 2021, then plummeted by 35.64% to $177000.0 in 2022, then plummeted by 103.39% to -$6000.0 in 2023, then skyrocketed by 66.67% to -$2000.0 in 2025.
  • Its Other financing activities was -$2000.0 in Q3 2025, compared to $2000.0 in Q2 2025 and -$1000.0 in Q1 2025.